Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.41 |
| ▸ | CALCR | P30988 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.38 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 2/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569246 | 0.95 | NTSR1 (0.44) | PTPN1NTSR1OPRD1XIAPAPLNR | |
| SCHEMBL29800885 | 0.93 | NAA50 (0.47) | PTPN1NAA50NTSR1OPRD1APLNR | |
| SCHEMBL29800900 | 0.92 | NTSR1 (0.48) | PTPN1NTSR1OPRD1XIAPNTSR2 | |
| SCHEMBL29399877 | 0.91 | NTSR1 (0.46) | PTPN1NTSR1OPRD1APLNRNTSR2 | |
| SCHEMBL29800934 | 0.90 | PTPN1 (0.42) | PTPN1NTSR1OPRD1XIAPAPLNR | |
| SCHEMBL29801129 | 0.89 | PTPN1 (0.45) | PTPN1NTSR1CALCROPRD1APLNR | |
| SCHEMBL31067238 | 0.88 | NTSR1 (0.50) | PTPN1NTSR1OPRD1NTSR2 | |
| SCHEMBL31670623 | 0.88 | XIAP (0.47) | PTPN1NAA50NTSR1OPRD1XIAP | |
| SCHEMBL29904041 | 0.87 | APLNR (0.41) | PTPN1NAA50NTSR1OPRD1APLNR | |
| SCHEMBL31067241 | 0.86 | NTSR1 (0.55) | NTSR1OPRD1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287147-A1 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287147-A1 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | PTPN1 1111/4885NAA50 4738/4885NTSR1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.